Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Bryan King, MD, MBA

    TitleProfessor
    SchoolUCSF School of Medicine
    DepartmentPsychiatry
    Address401 Parnassus Ave.
    San Francisco CA 94143
    Phone415-502-1980
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      University of California, IrvineBSBiological Sciences1979
      Medical College of WisconsinMD Medicine1983
      UCLA Center for Health SciencesInternshipInternal Medicine1984
      UCLA Neuropsychiatric InstituteResidency in PsychiatryPsychiatry1987
      UCLA Neuropsychiatric InstituteFellowship in Child and Adolescent PsychiatryPsychiatry1990
      George Washington UniversityMBABusiness2014
      Collapse Awards and Honors
      UC Irvine1979Phi Beta Kappa
      UC Irvine1979Magna Cum Laude
      UC Irvine1979Honors in Research
      NIMH1988Individual Research Service Award
      UCLA Neuropsychiatric Institute1988Gertrude Rogers Greenblatt Fellowship
      American Academy of Child and Adolescent Psychiatry1990George Tarjan Award
      UCLA Neuropsychiatric Institute Department of Nursing1997Outstanding Physician Award
      UCLA Neuropsychiatric Institute Department of Psychiatry1997Outstanding Mentor Award
      American Psychiatric Association2001Frank J. Menolascino Award
      Seattle Children's Hospital Family Advisory Council2007Annual Family Choice Award
      American Academy of Child and Adolescent Psychiatry2011Distinguished Fellow
      George Washington University School of Business2014Beta Gamma Sigma International Business Honor Society
      American Psychiatric Association2015Fellow

      Collapse Overview 
      Collapse Overview
      My research and clinical work has largely focused on psychiatric aspects of developmental disorders, and upon the pathogenesis and treatment of significant behavioral disturbance in autism and related disorders in particular. In recent years, this focus has been primarily directed on interventions in autism including both pharmacological and psychosocial treatments.


      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Veenstra-VanderWeele J, Cook EH, King BH, Zarevics P, Cherubini M, Walton-Bowen K, Bear MF, Wang PP, Carpenter RL. Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial. Neuropsychopharmacology. 2016 Nov 09. PMID: 27748740.
        View in: PubMed
      2. Jane Webb S, Garrison MM, Bernier R, McClintic AM, King BH, Mourad PD, et al. Severity of ASD symptoms and their correlation with the presence of copy number variations and exposure to first trimester ultrasound. Autism Res. 2016 Sep 1. PMID: 27582229.
        View in: PubMed
      3. Stein MA, King BH. Unequal Individual Risk and Potential Benefit Balanced by Benefits to the Population at Large in Autism Clinical Trials? Am J Bioeth. 2016 Apr; 16(4):72-4. PMID: 26982936.
        View in: PubMed
      4. King BH. Psychiatric comorbidities in neurodevelopmental disorders. Curr Opin Neurol. 2016 Apr; 29(2):113-7. PMID: 26840045.
        View in: PubMed
      5. King BH. Assessing Risk of Autism Spectrum Disorder in Children After Antidepressant Use During Pregnancy. JAMA Pediatr. 2016 Feb 1; 170(2):111-2. PMID: 26660503.
        View in: PubMed
      6. Kasari C, Dean M, Kretzmann M, Shih W, Orlich F, Whitney R, Landa R, Lord C, King B. Children with autism spectrum disorder and social skills groups at school: a randomized trial comparing intervention approach and peer composition. J Child Psychol Psychiatry. 2016 Feb; 57(2):171-9. PMID: 26391889.
        View in: PubMed
      7. Scahill L, McCracken JT, King BH, Rockhill C, Shah B, Politte L, Sanders R, Minjarez M, Cowen J, Mullett J, Page C, Ward D, Deng Y, Loo S, Dziura J, McDougle CJ. Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. Am J Psychiatry. 2015 Dec 1; 172(12):1197-206. PMID: 26315981.
        View in: PubMed
      8. Carr T, Shih W, Lawton K, Lord C, King B, Kasari C. The relationship between treatment attendance, adherence, and outcome in a caregiver-mediated intervention for low-resourced families of young children with autism spectrum disorder. Autism. 2016 Aug; 20(6):643-52. PMID: 26290524.
        View in: PubMed
      9. King BH. Promising forecast for autism spectrum disorders. JAMA. 2015 Apr 21; 313(15):1518-9. PMID: 25898047.
        View in: PubMed
      10. de Vries PJ, Whittemore VH, Leclezio L, Byars AW, Dunn D, Ess KC, Hook D, King BH, Sahin M, Jansen A. Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist. Pediatr Neurol. 2015 Jan; 52(1):25-35. PMID: 25532776; PMCID: PMC4427347.
      11. Dean M, Kasari C, Shih W, Frankel F, Whitney R, Landa R, Lord C, Orlich F, King B, Harwood R. The peer relationships of girls with ASD at school: comparison to boys and girls with and without ASD. J Child Psychol Psychiatry. 2014 Nov; 55(11):1218-25. PMID: 25039696; PMCID: PMC4269475.
      12. Kasari C, Lawton K, Shih W, Barker TV, Landa R, Lord C, Orlich F, King B, Wetherby A, Senturk D. Caregiver-mediated intervention for low-resourced preschoolers with autism: an RCT. Pediatrics. 2014 Jul; 134(1):e72-9. PMID: 24958585; PMCID: PMC4531276.
      13. Lecavalier L, Wood JJ, Halladay AK, Jones NE, Aman MG, Cook EH, Handen BL, King BH, Pearson DA, Hallett V, Sullivan KA, Grondhuis S, Bishop SL, Horrigan JP, Dawson G, Scahill L. Measuring anxiety as a treatment endpoint in youth with autism spectrum disorder. J Autism Dev Disord. 2014 May; 44(5):1128-43. PMID: 24158679; PMCID: PMC3981870.
      14. King BH. Sunsetting DSM-IV's pervasive developmental disorder. J Am Acad Child Adolesc Psychiatry. 2014 May; 53(5):494-6. PMID: 24745948.
        View in: PubMed
      15. Erickson CA, Veenstra-Vanderweele JM, Melmed RD, McCracken JT, Ginsberg LD, Sikich L, Scahill L, Cherubini M, Zarevics P, Walton-Bowen K, Carpenter RL, Bear MF, Wang PP, King BH. STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study. J Autism Dev Disord. 2014 Apr; 44(4):958-64. PMID: 24272415.
        View in: PubMed
      16. King BH, Navot N, Bernier R, Webb SJ. Update on diagnostic classification in autism. Curr Opin Psychiatry. 2014 Mar; 27(2):105-9. PMID: 24441420.
        View in: PubMed
      17. Hilt RJ, Chaudhari M, Bell JF, Wolf C, Koprowicz K, King BH. Side effects from use of one or more psychiatric medications in a population-based sample of children and adolescents. J Child Adolesc Psychopharmacol. 2014 Mar; 24(2):83-9. PMID: 24506790; PMCID: PMC3967377.
      18. Volkmar F, Siegel M, Woodbury-Smith M, King B, McCracken J, State M. Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2014 Feb; 53(2):237-57. PMID: 24472258.
        View in: PubMed
      19. Hilt R, Wolf C, Koprowicz K, Thomas E, Chandler M, Hao XL, Russell M, Le T, Hooks L, King B. Community child psychiatric medication experiences measured by an internet-based, prospective parent survey of retail pharmacy customers. Community Ment Health J. 2014 Feb; 50(2):172-8. PMID: 24323138.
        View in: PubMed
      20. Scahill L, Aman MG, Lecavalier L, Halladay AK, Bishop SL, Bodfish JW, Grondhuis S, Jones N, Horrigan JP, Cook EH, Handen BL, King BH, Pearson DA, McCracken JT, Sullivan KA, Dawson G. Measuring repetitive behaviors as a treatment endpoint in youth with autism spectrum disorder. Autism. 2015 Jan; 19(1):38-52. PMID: 24259748.
        View in: PubMed
      21. McClintic AM, King BH, Webb SJ, Mourad PD. Mice exposed to diagnostic ultrasound in utero are less social and more active in social situations relative to controls. Autism Res. 2014 Jun; 7(3):295-304. PMID: 24249575; PMCID: PMC4025980.
      22. King BH, Dukes K, Donnelly CL, Sikich L, McCracken JT, Scahill L, Hollander E, Bregman JD, Anagnostou E, Robinson F, Sullivan L, Hirtz D. Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial. JAMA Pediatr. 2013 Nov; 167(11):1045-52. PMID: 24061784.
        View in: PubMed
      23. Scahill L, Dimitropoulos A, McDougle CJ, Aman MG, Feurer ID, McCracken JT, Tierney E, Pu J, White S, Lecavalier L, Hallett V, Bearss K, King B, Arnold LE, Vitiello B. Children's Yale-Brown obsessive compulsive scale in autism spectrum disorder: component structure and correlates of symptom checklist. J Am Acad Child Adolesc Psychiatry. 2014 Jan; 53(1):97-107.e1. PMID: 24342389; PMCID: PMC3999641.
      24. Marrus N, Veenstra-Vanderweele J, Hellings JA, Stigler KA, Szymanski L, King BH, Carlisle LL, Cook EH, Pruett JR. Training of child and adolescent psychiatry fellows in autism and intellectual disability. Autism. 2014 May; 18(4):471-5. PMID: 24113341.
        View in: PubMed
      25. Hallett V, Lecavalier L, Sukhodolsky DG, Cipriano N, Aman MG, McCracken JT, McDougle CJ, Tierney E, King BH, Hollander E, Sikich L, Bregman J, Anagnostou E, Donnelly C, Katsovich L, Dukes K, Vitiello B, Gadow K, Scahill L. Exploring the manifestations of anxiety in children with autism spectrum disorders. J Autism Dev Disord. 2013 Oct; 43(10):2341-52. PMID: 23400347; PMCID: PMC4038127.
      26. Krueger DA, Northrup H. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013 Oct; 49(4):255-65. PMID: 24053983; PMCID: PMC4058297.
      27. Northrup H, Krueger DA. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013 Oct; 49(4):243-54. PMID: 24053982; PMCID: PMC4080684.
      28. Siegel M, King BH. Autism and developmental disorders: management of serious behavioral disturbance. Child Adolesc Psychiatr Clin N Am. 2014 Jan; 23(1):xiii-xv. PMID: 24231174.
        View in: PubMed
      29. King BH, de Lacy N, Siegel M. Psychiatric assessment of severe presentations in autism spectrum disorders and intellectual disability. Child Adolesc Psychiatr Clin N Am. 2014 Jan; 23(1):1-14. PMID: 24231163.
        View in: PubMed
      30. Berry-Kravis E, Hessl D, Abbeduto L, Reiss AL, Beckel-Mitchener A, Urv TK. Outcome measures for clinical trials in fragile X syndrome. J Dev Behav Pediatr. 2013 Sep; 34(7):508-22. PMID: 24042082; PMCID: PMC3784007.
      31. King BH, Veenstra-Vanderweele J, Lord C. DSM-5 and autism: kicking the tires and making the grade. J Am Acad Child Adolesc Psychiatry. 2013 May; 52(5):454-7. PMID: 23622845.
        View in: PubMed
      32. Sterling L, Munson J, Estes A, Murias M, Webb SJ, King B, Dawson G. Fear-potentiated startle response is unrelated to social or emotional functioning in adolescents with autism spectrum disorders. Autism Res. 2013 Oct; 6(5):320-31. PMID: 23495221; PMCID: PMC4141562.
      33. de Lacy N, King BH. Revisiting the relationship between autism and schizophrenia: toward an integrated neurobiology. Annu Rev Clin Psychol. 2013; 9:555-87. PMID: 23537488.
        View in: PubMed
      34. Fatemi SH, Aldinger KA, Ashwood P, Bauman ML, Blaha CD, Blatt GJ, Chauhan A, Chauhan V, Dager SR, Dickson PE, Estes AM, Goldowitz D, Heck DH, Kemper TL, King BH, Martin LA, Millen KJ, Mittleman G, Mosconi MW, Persico AM, Sweeney JA, Webb SJ, Welsh JP. Consensus paper: pathological role of the cerebellum in autism. Cerebellum. 2012 Sep; 11(3):777-807. PMID: 22370873; PMCID: PMC3677555.
      35. Swedo SE, Baird G, Cook EH, Happé FG, Harris JC, Kaufmann WE, King BH, Lord CE, Piven J, Rogers SJ, Spence SJ, Wetherby A, Wright HH. Commentary from the DSM-5 Workgroup on Neurodevelopmental Disorders. J Am Acad Child Adolesc Psychiatry. 2012 Apr; 51(4):347-9. PMID: 22449639.
        View in: PubMed
      36. Scahill L, McCracken JT, Bearss K, Robinson F, Hollander E, King B, Bregman J, Sikich L, Dukes K, Sullivan L, Anagnostou E, Donnelly C, Kim YS, Ritz L, Hirtz D, Wagner A. Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders. J Autism Dev Disord. 2012 Mar; 42(3):432-40. PMID: 21667200.
        View in: PubMed
      37. King BH, Lord C. Is schizophrenia on the autism spectrum? Brain Res. 2011 Mar 22; 1380:34-41. PMID: 21078305.
        View in: PubMed
      38. Yen CF, King BH, Tang TC. The association between short and long nocturnal sleep durations and risky behaviours and the moderating factors in Taiwanese adolescents. Psychiatry Res. 2010 Aug 30; 179(1):69-74. PMID: 20472300.
        View in: PubMed
      39. Yen CF, King BH, Chang YP. Factor structure of the Athens Insomnia Scale and its associations with demographic characteristics and depression in adolescents. J Sleep Res. 2010 Mar; 19(1 Pt 1):12-8. PMID: 19682243.
        View in: PubMed
      40. King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, Donnelly CL, Anagnostou E, Dukes K, Sullivan L, Hirtz D, Wagner A, Ritz L. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry. 2009 Jun; 66(6):583-90. PMID: 19487623; PMCID: PMC4112556.
      41. Brkanac Z, Raskind WH, King BH, et al. Pharmacology and genetics of autism: implications for diagnosis and treatment. Per Med. 2008 Nov; 5(6):599-607. PMID: 19727434.
        View in: PubMed
      42. Toth K, King BH. Asperger's syndrome: diagnosis and treatment. Am J Psychiatry. 2008 Aug; 165(8):958-63. PMID: 18676600.
        View in: PubMed
      43. King BH, Bostic JQ. An update on pharmacologic treatments for autism spectrum disorders. Child Adolesc Psychiatr Clin N Am. 2006 Jan; 15(1):161-75. PMID: 16321729.
        View in: PubMed
      44. Bostic JQ, King BH. Autism spectrum disorders: emerging pharmacotherapy. Expert Opin Emerg Drugs. 2005 Aug; 10(3):521-36. PMID: 16083327.
        View in: PubMed
      45. de Vries P, Humphrey A, McCartney D, Prather P, Bolton P, Hunt A. Consensus clinical guidelines for the assessment of cognitive and behavioural problems in Tuberous Sclerosis. Eur Child Adolesc Psychiatry. 2005 Jul; 14(4):183-90. PMID: 15981129.
        View in: PubMed
      46. Cromwell HC, King BH. . International Review of Research in Mental Retardation. The role of the basal ganglia in the expression of stereotyped, self-injurious behaviors in developmental disorders. 2004; 29:120-158.
      47. Aman MG, Novotny S, Samango-Sprouse C, Lecavalier L, Leonard E, Gadow KD, King BH, Pearson DA, Gernsbacher MA, Chez M. Outcome measures for clinical drug trials in autism. CNS Spectr. 2004 Jan; 9(1):36-47. PMID: 14999174; PMCID: PMC4441220.
      48. Hollander E, Phillips A, King BH, Guthrie D, Aman MG, Law P, Owley T, Robinson R. Impact of recent findings on study design of future autism clinical trials. CNS Spectr. 2004 Jan; 9(1):49-56. PMID: 14999175.
        View in: PubMed
      49. Foster B, King BH. Asperger syndrome: to be or not to be? Curr Opin Pediatr. 2003 Oct; 15(5):491-4. PMID: 14508298.
        View in: PubMed
      50. Dykens EM, Shah B, Sagun J, Beck T, King BH. Maladaptive behaviour in children and adolescents with Down's syndrome. J Intellect Disabil Res. 2002 Sep; 46(Pt 6):484-92. PMID: 12354319.
        View in: PubMed
      51. Stoddard FJ, Sheridan RL, Saxe GN, King BS, King BH, Chedekel DS, Schnitzer JJ, Martyn JA. Treatment of pain in acutely burned children. J Burn Care Rehabil. 2002 Mar-Apr; 23(2):135-56. PMID: 11882804.
        View in: PubMed
      52. Lewis MA, Lewis CE, Leake B, King BH, Lindemann R. The quality of health care for adults with developmental disabilities. Public Health Rep. 2002 Mar-Apr; 117(2):174-84. PMID: 12357002; PMCID: PMC1497422.
      53. King BH. . Pharmacotherapy in mental retardation. Current Opinion in Psychiatry. 2002; 15:497-502.
      54. Mikhail AG, King BH. Autism spectrum disorders: update of evaluation and treatment. Curr Psychiatry Rep. 2001 Oct; 3(5):361-5. PMID: 11559471.
        View in: PubMed
      55. King BH, Wright DM, Handen BL, Sikich L, Zimmerman AW, McMahon W, Cantwell E, Davanzo PA, Dourish CT, Dykens EM, Hooper SR, Jaselskis CA, Leventhal BL, Levitt J, Lord C, Lubetsky MJ, Myers SM, Ozonoff S, Shah BG, Snape M, Shernoff EW, Williamson K, Cook EH. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2001 Jun; 40(6):658-65. PMID: 11392343.
        View in: PubMed
      56. King BH, Wright DM, Snape M, Dourish CT. Case series: amantadine open-label treatment of impulsive and aggressive behavior in hospitalized children with developmental disabilities. J Am Acad Child Adolesc Psychiatry. 2001 Jun; 40(6):654-7. PMID: 11392342.
        View in: PubMed
      57. Schroeder SR, Oster-Granite ML, Berkson G, Bodfish JW, Breese GR, Cataldo MF, Cook EH, Crnic LS, DeLeon I, Fisher W, Harris JC, Horner RH, Iwata B, Jinnah HA, King BH, Lauder JM, Lewis MH, Newell K, Nyhan WL, Rojahn J, Sackett GP, Sandman C, Symons F, Tessel RE, Thompson T, Wong DF. Self-injurious behavior: gene-brain-behavior relationships. Ment Retard Dev Disabil Res Rev. 2001; 7(1):3-12. PMID: 11241877.
        View in: PubMed
      58. Mikhail AG, King BH. . Self-injurious behaviour in mental retardation. Current Opinion in Psychiatry. 2001; 14:457-461.
      59. King BH. Pharmacological treatment of mood disturbances, aggression, and self-injury in persons with pervasive developmental disorders. J Autism Dev Disord. 2000 Oct; 30(5):439-45. PMID: 11098881.
        View in: PubMed
      60. et al. Expert Consensus Guideline Series: Treatment of psychiatric and behavioral problems in mental retardation. Am J Ment Retard. 2000 May; 105(3):159-226. PMID: 10907489.
        View in: PubMed
      61. LaHoste GJ, Wigal T, King BH, Schuck SE, Crinella FM, Swanson JM. Carbamazepine reduces dopamine-mediated behavior in chronic neuroleptic-treated and untreated rats: implications for treatment of tardive dyskinesia and hyperdopaminergic states. Exp Clin Psychopharmacol. 2000 Feb; 8(1):125-32. PMID: 10743913.
        View in: PubMed
      62. Madrid AL, State MW, King BH. Pharmacologic management of psychiatric and behavioral symptoms in mental retardation. Child Adolesc Psychiatr Clin N Am. 2000 Jan; 9(1):225-43, x-xi. PMID: 10674198.
        View in: PubMed
      63. Szymanski L, King BH. Practice parameters for the assessment and treatment of children, adolescents, and adults with mental retardation and comorbid mental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. J Am Acad Child Adolesc Psychiatry. 1999 Dec; 38(12 Suppl):5S-31S. PMID: 10624083.
        View in: PubMed
      64. Szymanski L, King BH. Summary of the Practice Parameters for the Assessment and Treatment of Children, Adolescents, and Adults with Mental Retardation and Comorbid Mental Disorders. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1999 Dec; 38(12):1606-10. PMID: 10596263.
        View in: PubMed
      65. State MW, Dykens EM, Rosner B, Martin A, King BH. Obsessive-compulsive symptoms in Prader-Willi and "Prader-Willi-Like" patients. J Am Acad Child Adolesc Psychiatry. 1999 Mar; 38(3):329-34. PMID: 10087695.
        View in: PubMed
      66. Cromwell HC, Levine MS, King BH. Cortical damage enhances pemoline-induced self-injurious behavior in prepubertal rats. Pharmacol Biochem Behav. 1999 Feb; 62(2):223-7. PMID: 9972687.
        View in: PubMed
      67. Dykens EM, Cassidy SB, King BH. Maladaptive behavior differences in Prader-Willi syndrome due to paternal deletion versus maternal uniparental disomy. Am J Ment Retard. 1999 Jan; 104(1):67-77. PMID: 9972835.
        View in: PubMed
      68. Racusin R, Kovner-Kline K, King BH. . Selective serotonin re-uptake inhibitors in intellectual disability. Mental Retardation and Developmental Disabilities Research Reviews. 1999; 5:264-269.
      69. Philibert RA, King BH, Winfield S, Cook EH, Lee YH, Stubblefield B, Damschroder-Williams P, Dea C, Palotie A, Tengstrom C, Martin BM, Ginns EI. Association of an X-chromosome dodecamer insertional variant allele with mental retardation. Mol Psychiatry. 1998 Jul; 3(4):303-9. PMID: 9702738.
        View in: PubMed
      70. Jacobsen J, King BH, Leventhal BL, Christian SL, Ledbetter DH, Cook EH. Molecular screening for proximal 15q abnormalities in a mentally retarded population. J Med Genet. 1998 Jul; 35(7):534-8. PMID: 9678696; PMCID: PMC1051362.
      71. Davanzo PA, Belin TR, Widawski MH, King BH. Paroxetine treatment of aggression and self-injury in persons with mental retardation. Am J Ment Retard. 1998 Mar; 102(5):427-37. PMID: 9544340.
        View in: PubMed
      72. King BH, Cromwell HC, Lee HT, Behrstock SP, Schmanke T, Maidment NT. Dopaminergic and glutamatergic interactions in the expression of self-injurious behavior. Dev Neurosci. 1998; 20(2-3):180-7. PMID: 9691192.
        View in: PubMed
      73. Krishnamoorthy J, King BH. Open-label olanzapine treatment in five preadolescent children. J Child Adolesc Psychopharmacol. 1998; 8(2):107-13. PMID: 9730076.
        View in: PubMed
      74. King BH, Lynn D. . Self-injurious behaviour in mental retardation. Current Opinion in Psychiatry. 1998; 11:523-526.
      75. King BH, Krishnamurthy J. . Developmental aspects of stereotyped movement disorder. Psychiatric Annals. 1998; 28:313-316.
      76. Davanzo PA, Ke Y, King BH, Guze BH, McCracken J, Curran J, Thomas A. . Proton MR spectroscopy in four patients with Lesch-Nyhan Disease. American Journal of Neuroradiology. 1998; 19:672-674.
      77. State MW, King BH, Dykens E. Mental retardation: a review of the past 10 years. Part II. J Am Acad Child Adolesc Psychiatry. 1997 Dec; 36(12):1664-71. PMID: 9401327.
        View in: PubMed
      78. King BH, State MW, Shah B, Davanzo P, Dykens E. Mental retardation: a review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry. 1997 Dec; 36(12):1656-63. PMID: 9401326.
        View in: PubMed
      79. et al. Issues to consider in deaf and hard-of-hearing patients. The Committee on Disabilities of the Group for the Advancement of Psychiatry. Am Fam Physician. 1997 Nov 15; 56(8):2057-64, 2067-8. PMID: 9390099.
        View in: PubMed
      80. Dykens EM, Goff BJ, Hodapp RM, Davis L, Devanzo P, Moss F, Halliday J, Shah B, State M, King B. Eating themselves to death: have "personal rights" gone too far in treating people with Prader-Willi syndrome? Ment Retard. 1997 Aug; 35(4):312-4. PMID: 9270240.
        View in: PubMed
      81. et al. Child and learning disability psychopharmacology. J Psychopharmacol. 1997; 11(4):291-4. PMID: 9443515.
        View in: PubMed
      82. Cromwell HC, King BH, Levine MS. Pemoline alters dopamine modulation of synaptic responses of neostriatal neurons in vitro. Dev Neurosci. 1997; 19(6):497-504. PMID: 9445087.
        View in: PubMed
      83. Cromwell HC, Witte EA, Crawford CA, Ly HT, Maidment NT, King BH. Pemoline produces ipsilateral turning behavior in unilateral 6-OHDA-lesioned rats. Prog Neuropsychopharmacol Biol Psychiatry. 1996 Apr; 20(3):503-14. PMID: 8771605.
        View in: PubMed
      84. Davanzo PA, King BH. Open trial lamotrigine in the treatment of self-injurious behavior in an adolescent with profound mental retardation. J Child Adolesc Psychopharmacol. 1996; 6(4):273-9. PMID: 9231320.
        View in: PubMed
      85. King BH, Davanzo P. . Buspirone treatment of aggression and self-injury in autistic and non autistic persons with severe mental retardation. Developmental Brain Dysfunction. 1996; 9:22-31.
      86. King BH, Au D, Poland RE. Pretreatment with MK-801 inhibits pemoline-induced self-biting behavior in prepubertal rats. Dev Neurosci. 1995; 17(1):47-52. PMID: 7621748.
        View in: PubMed
      87. King BH, DeAntonio C, McCracken JT, Forness SR, Ackerland V. Psychiatric consultation in severe and profound mental retardation. Am J Psychiatry. 1994 Dec; 151(12):1802-8. PMID: 7977889.
        View in: PubMed
      88. Forness SR, Kavale K, King BH, Kasari C. . Simple versus complex conduct disorders: Identification and phenomenology. Behavioral Disorders. 1994; 19:306-312.
      89. King BH. Self-injury by people with mental retardation: a compulsive behavior hypothesis. Am J Ment Retard. 1993 Jul; 98(1):93-112. PMID: 8373567.
        View in: PubMed
      90. King BH, Au D, Poland RE. Low-dose naltrexone inhibits pemoline-induced self-biting behavior in prepubertal rats. J Child Adolesc Psychopharmacol. 1993; 3(2):71-9. PMID: 19630639.
        View in: PubMed
      91. Yuwiler A, Shih JC, Chen CH, Ritvo ER, Hanna G, Ellison GW, King BH. Hyperserotoninemia and antiserotonin antibodies in autism and other disorders. J Autism Dev Disord. 1992 Mar; 22(1):33-45. PMID: 1375597.
        View in: PubMed
      92. King BH, Poland RE. Comments on self-injurious behaviour. Am J Psychiatry. 1991 Nov; 148(11):1617-8. PMID: 1928505.
        View in: PubMed
      93. King BH, McCracken JT, Poland RE. Deficiency in the opioid hypotheses of self-injurious behavior. Am J Ment Retard. 1991 May; 95(6):692-4; discussion 694-6. PMID: 1647799.
        View in: PubMed
      94. Brazell C, McClue SJ, Preston GC, King B, Stahl SM. 5-Hydroxytryptamine (5-HT)-induced shape change in human platelets determined by computerized data acquisition: correlation with [125I]-iodoLSD binding at 5-HT2 receptors. Blood Coagul Fibrinolysis. 1991 Feb; 2(1):17-24. PMID: 1772986.
        View in: PubMed
      95. King BH. Fluoxetine reduced self-injurious behavior in an adolescent with mental retardation. J Child Adolesc Psychopharmacol. 1991; 1(5):321-9. PMID: 19630681.
        View in: PubMed
      96. King BH. Hypothesis: involvement of the serotonergic system in the clinical expression of monosymptomatic hypochondriasis. Pharmacopsychiatry. 1990 Mar; 23(2):85-9. PMID: 2187212.
        View in: PubMed
      97. King BH, Liston EH. Proposals for the mechanism of action of convulsive therapy: a synthesis. Biol Psychiatry. 1990 Jan 1; 27(1):76-94. PMID: 1967536.
        View in: PubMed
      98. King BH, Brazell C, Dourish CT, Middlemiss DN. MK-212 increases rat plasma ACTH concentration by activation of the 5-HT1C receptor subtype. Neurosci Lett. 1989 Oct 23; 105(1-2):174-6. PMID: 2562060.
        View in: PubMed
      99. Ford CV, King BH, Hollender MH. Lies and liars: psychiatric aspects of prevarication. Am J Psychiatry. 1988 May; 145(5):554-62. PMID: 3282449.
        View in: PubMed
      100. King BH, Ford CV. Pseudologia fantastica. Acta Psychiatr Scand. 1988 Jan; 77(1):1-6. PMID: 3279719.
        View in: PubMed
      101. King BH, Baxter LR, Stuber M, Fish B. Therapeutic sleep deprivation for depression in children. J Am Acad Child Adolesc Psychiatry. 1987 Nov; 26(6):928-31. PMID: 3429415.
        View in: PubMed
      102. King BH, Ford CV. Pseudologia fantastica. Am J Psychiatry. 1987 Jul; 144(7):970-1. PMID: 3605419.
        View in: PubMed
      103. King BH, Bryant PJ. Developmental responses of the Drosophila melanogaster embryo to localized X irradiation. Radiat Res. 1982 Mar; 89(3):590-606. PMID: 6801720.
        View in: PubMed
      Back to TOP